- Previous Close
0.1132 - Open
0.1400 - Bid --
- Ask --
- Day's Range
0.1202 - 0.1400 - 52 Week Range
0.0950 - 7.8300 - Volume
75,613,035 - Avg. Volume
18,041,556 - Market Cap (intraday)
12.692M - Beta (5Y Monthly) 2.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
www.conduitpharma.comRecent News: CDT
View More
Performance Overview: CDT
Trailing total returns as of 10/23/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDT
View MoreValuation Measures
Market Cap
13.06M
Enterprise Value
13.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-322.02%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.69M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
433k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: CDT
CDT does not have Company Insights